Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug - STAT

What the report says

STAT reported that the Food and Drug Administration has challenged Capricor Therapeutics’ claims about deramiocel, its stem cell-based treatment for Duchenne muscular dystrophy, ahead of a regulatory hearing. According to STAT, the FDA said Monday that the therapy did not meet the goals of a Phase 3 trial, creating a direct contrast with Capricor’s December statement that the study had achieved both its primary and secondary endpoints.

The drug is being evaluated for Duchenne muscular dystrophy, a severe inherited muscle-wasting disease that primarily affects boys and often leads to progressive loss of mobility and heart complications. STAT noted that Capricor’s earlier interpretation of the data drew attention because the trial included many teenagers and young men who could no longer walk, a group with limited treatment options.

Capricor had said deramiocel appeared to help maintain upper-limb function and delay heart failure-related decline in patients, according to the article. The FDA’s contrary assessment adds uncertainty around the therapy’s prospects and sets up a potentially important advisory discussion for a rare disease area where regulators, companies and patient communities have often weighed imperfect evidence against high unmet need.

The available STAT article text does not include the FDA’s full reasoning, the hearing date, or Capricor’s latest detailed response. More information from briefing documents or the advisory meeting would be needed to assess how regulators view the trial design, endpoints and clinical significance of the results.